布地奈德福莫特罗粉吸入剂联合孟鲁司特钠治疗咳嗽变异性哮喘临床

龙源期刊网 http://www.qikan.com.cn

布地奈德福莫特罗粉吸入剂联合孟鲁司特钠治疗咳嗽变异性哮喘临床观察

作者：陈波勇 姜仁早 何淑梅

来源：《中国实用医药》2017年第08期

【摘要】 目的 探讨布地奈德福莫特罗粉吸入剂联合孟鲁司特钠在咳嗽变异性哮喘（CVA）患者中治疗效果。方法 80例CVA患者为研究对象， 采用信封分组法将患者分为A组和B组， 各40例。A组在B组单用布地奈德福莫特罗粉吸入剂基础上联合孟鲁司特钠治疗， 两组患者连续治疗2个月， 比较两组患者疗效及治疗前后咳嗽症状评分、咳嗽生活质量（采用LCQ问卷评价）及外周血免疫球蛋白E（IgE）水平。结果 A组患者临床治疗总有效率为97.50%， 明显高于B组的85.00%， 差异具有统计学意义（P0.05）；治疗后两组患者咳嗽症状、LCQ评分及IgE水平较治疗前均有显著改善， A组患者改善程度较B组更显著， 差异具有统计学意义（P

【关键词】 布地奈德福莫特罗粉吸入剂；孟鲁司特钠；咳嗽变异性哮喘 DOI：10.14163/j.cnki.11-5547/r.2017.08.056

【Abstract】 Objective To investigate curative effect by budesonide formoterol powder inhalation combined with montelukast sodium in the treatment of cough variant asthma （CVA）. Methods A total of 80 CVA patients as study subjects were divided by envelope method into group A and group B， with 40 cases in each group. Group B received budesonide formoterol powder inhalation， and group A received additional montelukast sodium for combined treatment. Their treatment all lasted for 2 months. Comparison was made on curative effects， cough symptom score， cough quality of life （Leicester cough questionnaire， LCQ） and peripheral blood immunoglobulin E （IgE） level between the two groups before and after treatment. Results Group A had obviously higher total effective rate in clinical treatment as 97.50% than 85.00%， and their difference had statistical significance （P0.05）. After treatment， both groups had obvious improvements in cough symptom score， LCQ score and IgE level， and group A had much better improvement than group B. Their difference had statistical significance （P

【Key words】 Budesonide formoterol powder inhalation； Montelukast sodium； Cough variant asthma

CVA为哮喘中特殊疾病类型之一， 以气道高反应为病理特征， 表现为慢性咳嗽、喘息， 对患者健康和生活质量均造成严重影响。长期呼吸道吸入解痉平喘药物为控制症状关键， 布地奈德福莫特罗粉吸入剂为新型混合型吸入药物， 吸入后在气道内局部具有较强抗炎、扩张

本文来源：https://www.bwwdw.com/article/sns7.html